Similar results were obtained by Rasouli et al., who found that TCD4+ lymphocytes in MS patients showed increased GM-CSF production, while the frequency of GM-CSF-producing T cells was reduced by immunotherapy [44]. Here, CSF2 is linked to myeloid sarcoma.